Retacrit(R) Demonstrates Efficacy And Safety In Chemotherapy-Induced Anaemia
Hospira (NYSE: HSP), the world leader in generic injectable pharmaceuticals, presented new data showing Retacrit® (epoetin zeta) is an effective treatment for chemotherapy-induced anaemia,1 with an acceptable safety and tolerability profile.2 Results from the Phase III trial were presented at the European Society for Medical Oncology (ESMO) congress.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment